Overall, our data have indicated that miR-431/Smad4 plays an important role in the pathogenesis of AD, and upregulating miR-431 and/or inhibiting Smad4 might be a potential therapeutic strategy for AD treatment. Here, SMAD4 is linked to Alzheimer disease.